CRISPR Therapeutics AG: Q1 2026 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2026, for CRISPR Therapeutics AG (CRSP), a biopharmaceutical company focused on CRISPR-based therapeutics. The company operates as a single segment dedicated to discovering, developing, and commercializing gene-editing therapies. Key programs include the approved hemoglobinopathy therapy CASGEVY (in collaboration with Vertex), in vivo liver editing candidates (CTX310, CTX340), CAR-T therapies (zugo-cel), and siRNA programs (CTX611) developed with Sirius Therapeutics.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $1.5 million | $0.9 million |
| Net Loss | $(122.9) million | $(136.0) million |
| Net Loss Per Share (Basic & Diluted) | $(1.28) | $(1.58) |
| Operating Expenses | $131.7 million | $149.3 million |
| Cash, Cash Equivalents, and Marketable Securities | $2,441.8 million | $1,975.8 million |
| Long-Term Debt | $585.5 million | $0 |
| Net Cash Used in Operating Activities | $(108.9) million | $(53.9) million |
Material Changes vs. Prior Period
- Debt Financing: In March 2026, the company issued $600.0 million in aggregate principal amount of Convertible Senior Notes due 2031. Net proceeds were approximately $585.4 million after issuance costs. This represents a significant increase in leverage compared to the prior year.
- Expense Reduction: Total operating expenses decreased by $17.6 million year-over-year. This was driven by a $11.6 million reduction in collaboration expenses (net) and a $3.9 million decrease in R&D expenses, primarily due to lower employee-related costs and stock-based compensation.
- Investing Activities: Net cash used in investing activities increased significantly to $410.7 million (from $19.8 million in Q1 2025), primarily due to a net increase in the purchase of marketable securities.
- Collaboration Revenue: Collaboration revenue increased to $1.0 million in Q1 2026 from $0 in Q1 2025, while grant revenue decreased to $0.5 million from $0.9 million.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($2.44 billion) to fund operating expenses and capital expenditures for at least the next 24 months, excluding potential proceeds from collaborations or additional capital raises.
- Debt Risks: The new $600 million debt obligation introduces risks regarding cash flow availability for operations and potential dilution if notes are converted. The notes have an effective coupon of 1.125% (grossed up to 1.7308% for tax withholding) and mature in March 2031.
- Legal Proceedings: The company was dismissed as a defendant in a patent infringement lawsuit initiated by ToolGen, Inc. in April 2026 without prejudice. Management notes that litigation outcomes remain uncertain and could adversely affect operations.
- Contingencies: A contingent liability of $14.5 million remains recorded regarding a third-party licensor engagement from 2025. The company cannot estimate a range of loss, and the ultimate resolution could exceed the accrued amount.
Investor Verification Checklist
- Verify the terms and conversion triggers of the newly issued $600 million Convertible Senior Notes due 2031.
- Monitor the status of the ToolGen patent litigation and any potential re-filing of claims.
- Review the progress of CASGEVY commercialization and the associated cost-sharing arrangements with Vertex.
- Assess the timeline and funding requirements for the Phase 2 trials of CTX611 (siRNA) and Phase 1b trials of CTX310 (in vivo liver editing).
- Confirm the sufficiency of the $2.44 billion cash position against projected burn rates for the next 24 months.